A Cost-Effectiveness Analysis

METHODS: We created a decision analytic model that compared the cost effectiveness (eg, the marginal cost of the strategy in U.S. dollars divided by the marginal effectiveness of the strategy, measured in qualityadjusted life-years [QALYs]) of initiation of methadone, buprenorphine, or detoxification in treatment of OUD during pregnancy. Probabilities, costs, and utilities were estimated from the existing literature. Incremental costeffective ratios for each strategy were calculated, and a ratio of $100,000 per QALY was used to define cost effectiveness. One-way sensitivity analyses and a Monte Carlo probabilistic sensitivity analysis were performed.

[1]  C. Guille,et al.  Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine. , 2019, American journal of obstetrics and gynecology.

[2]  W. Callaghan,et al.  Opioid Use Disorder Documented at Delivery Hospitalization — United States, 1999–2014 , 2018, MMWR. Morbidity and mortality weekly report.

[3]  T. Wilens,et al.  Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts. , 2018, Obstetrics and gynecology.

[4]  Na Wang,et al.  Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality , 2018, Annals of Internal Medicine.

[5]  H. Jones,et al.  Opioid Detoxification During Pregnancy: A Systematic Review. , 2018, Obstetrics and gynecology.

[6]  Matthew M Davis,et al.  Incidence and Costs of Neonatal Abstinence Syndrome Among Infants With Medicaid: 2004–2014 , 2018, Pediatrics.

[7]  N. Riblet,et al.  Association of Rooming-in With Outcomes for Neonatal Abstinence Syndrome: A Systematic Review and Meta-analysis , 2018, JAMA pediatrics.

[8]  R. Platt,et al.  Methadone Versus Buprenorphine for Opioid Use Dependence and Risk of Neonatal Abstinence Syndrome , 2017, Epidemiology.

[9]  M. Brolin,et al.  Design and impact of bundled payment for detox and follow-up care. , 2017, Journal of substance abuse treatment.

[10]  Xuan Yang,et al.  Monetary conversion factors for economic evaluations of substance use disorders. , 2017, Journal of substance abuse treatment.

[11]  G. Hulse,et al.  Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone. , 2017, The International journal on drug policy.

[12]  L. Degenhardt,et al.  Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies , 2017, British Medical Journal.

[13]  H. Cabral,et al.  The Prevalence and Impact of Substance Use Disorder and Treatment on Maternal Obstetric Experiences and Birth Outcomes Among Singleton Deliveries in Massachusetts , 2017, Maternal and Child Health Journal.

[14]  B. Vohr,et al.  Survival and Neurodevelopmental Outcomes among Periviable Infants , 2017, The New England journal of medicine.

[15]  C. Towers,et al.  Detoxification from opiate drugs during pregnancy. , 2016, American journal of obstetrics and gynecology.

[16]  S. Park,et al.  Factors associated with buprenorphine versus methadone use in pregnancy , 2016, Substance abuse.

[17]  U. Reddy,et al.  Trends in Stillbirth by Gestational Age in the United States, 2006–2012 , 2015, Obstetrics and gynecology.

[18]  K. Kampman,et al.  American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use , 2015, Journal of addiction medicine.

[19]  Monica Bennett,et al.  Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs , 2015 .

[20]  M. Thoma,et al.  Infant Mortality Statistics From the 2013 Period Linked Birth/Infant Death Data Set. , 2015, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[21]  Matthew M Davis,et al.  Increasing Incidence and Geographic Distribution of Neonatal Abstinence Syndrome: United States 2009-2012 , 2015, Journal of Perinatology.

[22]  S. Heil,et al.  Methadone and Buprenorphine for Opioid Dependence During Pregnancy: A Retrospective Cohort Study , 2015, Journal of addiction medicine.

[23]  Joshua T. Cohen,et al.  Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.

[24]  D. Thomas,et al.  Neonatal Abstinence Syndrome , 2014, Pediatrics.

[25]  D. Nelson,et al.  The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. , 2013, American journal of obstetrics and gynecology.

[26]  P. Alexandre,et al.  The Economic Cost of Substance Abuse Treatment in the State of Florida , 2012, Evaluation review.

[27]  K. Barnhart,et al.  A cost-effectiveness analysis of surgical versus medical management of early pregnancy loss. , 2012, Fertility and sterility.

[28]  Bruce R. Schackman,et al.  Cost-Effectiveness of Long-Term Outpatient Buprenorphine-Naloxone Treatment for Opioid Dependence in Primary Care , 2012, Journal of General Internal Medicine.

[29]  T. Fahey,et al.  Methadone and perinatal outcomes: a retrospective cohort study. , 2011, American journal of obstetrics and gynecology.

[30]  H. Jones,et al.  Neonatal abstinence syndrome after methadone or buprenorphine exposure. , 2010, The New England journal of medicine.

[31]  H. Glick,et al.  Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. , 2010, Addiction.

[32]  A. Carroll,et al.  Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. , 2009, The Journal of pediatrics.

[33]  N. Horton,et al.  Overdose after detoxification: a prospective study. , 2007, Drug and alcohol dependence.

[34]  Karalee Poschman,et al.  Cost of Hospitalization for Preterm and Low Birth Weight Infants in the United States , 2007, Pediatrics.

[35]  M. Connock,et al.  Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. , 2007, Health technology assessment.

[36]  B. Lester,et al.  Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. , 2005, Drug and alcohol dependence.

[37]  J. Strang,et al.  Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study , 2003, BMJ : British Medical Journal.

[38]  E. Pergament,et al.  Preference assessment of prenatal diagnosis for Down syndrome: is 35 years a rational cutoff? , 2002, Prenatal diagnosis.

[39]  M. Kuppermann,et al.  Procedure‐Related Miscarriages and Down Syndrome–Affected Births: Implications for Prenatal Testing Based on Women's Preferences , 2000, Obstetrics and gynecology.

[40]  S. Hutchinson,et al.  One-year follow-up of opiate injectors treated with oral methadone in a GP-centred programme. , 2000, Addiction.

[41]  Tammy O. Tengs,et al.  One thousand health-related quality-of-life estimates. , 2000, Medical care.

[42]  J. Dashe,et al.  Opioid Detoxification in Pregnancy , 1998, Obstetrics and gynecology.

[43]  A S Detsky,et al.  Primer on Medical Decision Analysis: Part 5—Working with Markov Processes , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[44]  F. Zuspan,et al.  Fetal stress from methadone withdrawal. , 1975, American journal of obstetrics and gynecology.

[45]  J. Rementería,et al.  Narcotic withdrawal in pregnancy: stillbirth incidence with a case report. , 1973, American journal of obstetrics and gynecology.

[46]  D. E. Statzer,et al.  Heroin addiction during pregnancy. , 1972, American journal of obstetrics and gynecology.

[47]  J. Martin,et al.  Births: Final Data for 2016. , 2018, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[48]  J. Marsden,et al.  Reductions in non-fatal overdose after drug misuse treatment: results from the National Treatment Outcome Research Study (NTORS). , 2002, Journal of substance abuse treatment.